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Conclusion
• In normal physiology, the heart achieves optimal cardiac output through the 
augmentation of stroke volume and heart rate. Myocardial contractility, the Frank-
Starling law of stretch, and afterload related to ventricular-atrial coupling a determine 
stroke volume. Diastole affects these components. In beginning diastole, elastic recoil 
relating to the Frank-Starling law and active myocardial relaxation creates a negative 
pressure gradient, allowing passive filling of the LV, which accounts for 80% of 
ventricular filling. Following this passive filling, the LA contraction, or “kick,” causes the 
remainder of ventricular filling. When the ventricle reaches its maximum fill capacity, 
contraction begins, beginning systole and ejecting blood from the heart. Diastole is an 
active process, meaning it requires energy in the form of ATP. Diastole is the process of 
the LV filling from the LA through the mitral valve. It is affected by plasma volume, 
passive elasticity, and active relaxation of the LV, and the volume and pressure 
received from the LA (Farris et al., 2017).
• HFpEF has two significant components: alteration of active ventricular relaxation and 
myocardial stiffness. 
• HFpEF impairs the active relaxation of the LV due to reduced cardiac myocyte ATP 
production related to the dysfunction of the mitochondria. A decrease in nitrous oxide 
(NO) production, an increase in reactive oxygen species, dysfunction of the 
endothelium, and ischemia of the microvasculature causes the dysfunction of the 
mitochondria. Because of the decrease in ATP production, the cardiomyocytes are 
unable to uptake calcium into the sarcoplasmic reticulum appropriately, which 
prevents calcium from unbinding to troponin. This calcium mismanagement leaves the 
myofilaments unable to uncouple, preventing active relaxation (Farris et al., 2017). 
• The myocardium becomes stiff in HFpEF due to sarcomere dysfunction and an increase 
in extracellular matrix proteins. In a non-diseased resting heart, the action of titin 
protein located in the sarcomeres mediates ventricular stiffness and tension. Titin 
works as a bidirectional spring and plays a part in early diastolic passive recoil. In 
HFpEF, the titin protein does not phosphorylate normally and causes an increase in 
resting myocardial stiffness. Excessive extracellular matrix protein production causes 
fibrosis and myocardial stiffness in HFpEF by binding to the collagen matrix, 
cardiomyocytes, and fibroblasts (Farris et al., 2017).
• Because of the impaired relaxation and myocardial stiffness associated with HFpEF, the 
heart must work harder to achieve the same ejection fraction (EF). In order to maintain 
the necessary EF, the cardiomyocytes may hypertrophy, causing enlargement of the 
heart. This enlargement can decrease stroke volume due to reduced available filling 
space while not affecting contractility. The enlargement of the cardiac muscle 
maintains the ejection fraction, which is stroke volume divided by end-diastolic 
volume, or the volume in the heart after ventricular filling has occurred before the 
start of systole. Because the pathophysiology of HFpEF causes a reduction of both 
stroke volume and end-diastolic volume, the EF is preserved, remaining > 50% (Farris 
et al., 2017).
Underlying Pathophysiology
Significance of Pathophysiology
• Heart failure with preserved ejection 
fraction (HFpEF), formerly known as 
diastolic heart failure, is a diagnosis that 
is becoming more prevalent as the 
population ages. HFpEF affects 10 in 
every 1,000 individuals over 65 years of 
age, with 870,000 new cases being 
diagnosed every year (Tawil & Gelzinis, 
2016).
• HFpEF accounts for 54% of all heart 
failure diagnoses. The five year
mortality for patients with HFpEF is 
42.3% (Singh & Mehta, 2018).
• HFpEF is a clinical syndrome that 
encompasses several cardiovascular 
disease processes and symptoms that 
relate to diastolic dysfunction while 
retaining a left ventricular ejection 
fraction (LVEF) of > 50% (Harper, Patel, 
& Lyon (2018).
• HFpEF requires careful consideration of 
the healthcare provider when exploring 
clinical decisions relating to the 
management of the disease and 
beyond.
Topic Importance
• As the population ages, HFpEF is
becoming more prevalent. It is the 
leading cause of hospitalization in 
patients 65 and older (Tawil & Gelzinis, 
2016).
• The management of HFpEF creates 
unique challenges for the anesthesia 
provider and intraoperative clinical 
management and decision making, and 
the disease is associated with increased 
mortality postoperatively (Singh & 
Mehta, 2018).
• Health care expenses related to heart
failure totaled $30 billion in 2013 
(Gazewood & Turner, 2017).
• In the next 20 years the prevalence of
heart failure is projected to increase by 
50% (Farris et al., 2017). 
Risk Factors
• Age > 70
• Female sex
• Obesity
• Hypertension
• Tobacco use
• Diabetes mellitus
• Coronary artery disease
• Valvular heart disease
• Atrial fibrillation
(Gazewood & Turner, 2013)
• HFpEF consists of a combination of cardiovascular disease processes that become 
prevalent in advanced age. As the patient ages, the cardiomyocyte function 
degrades, and the production and utilization of ATP decreases cause the inability of 
the ventricles to relax as well as stiffness resulting in issues with ventricular 
compliance and filling (Singh & Mehta, 2018).
• As the heart works to maintain the same contractility to deliver oxygen to the 
tissues, the walls may hypertrophy to elicit a greater pressure gradient and 
overcome the cardiac wall stiffness and impair relaxation (Farris et al., 2017).
• As the heart continues to fail, symptoms of HFpEF may arise, such as fatigue, 
dyspnea on exertion, and edema (Gazewood & Turner, 2017).
• On the onset of symptoms, the patient may seek treatment. The diagnosis of 
HFpEF consists of the presence of signs and symptoms of heart failure, and 
echocardiogram confirming LVEF > 50%, and a beta-natriuretic peptide (BNP) of >
100 pg/mL (Tawil & Gelzinis, 2016).
• Because the pathophysiology of HFpEF is irreversible, there is no treatment
available. However, the symptoms of HFpEF can be managed with diet and lifestyle 
changes, as well as medications such as diuretics to reduce preload, beta blockers 
to reduce afterload, and ACE inhibitors to prevent further remodeling of the 
myocardial tissue (Harper et al., 2017).
• HFpEF is a chronic disease that when diagnosed will be present for the remainder 
of the patient’s lifetime. 
• General fatigue and weakness
• Dyspnea, paroxysmal nocturnal dyspnea, or orthopnea
• Edema
• Jugular venous distension
• S3 heart sound
• Displaced apical impulse
(Gazewood & Turner, 2017)
• The management of HFpEF requires 
diet and lifestyle changes, as well 
has a strict medication regimen.
• The nurse has an important role in 
the education of the HFpEF patient 
on these expectations for 
prevention of clinical deterioration 
and an acute on chronic 
exacerbation (Cavalcanti & Pereira, 
2014).
• Patients that develop an acute on 
chronic exacerbation of HFpEF may 
be admitted to inpatient units. In 
this case, the nurse must be aware 
that the patient could exhibit 
exercise intolerance and shortness 
of breath. This may impede nursing 
care and require management in an 
acute care setting (Gazewood & 
Turner, 2017).
• HFpEF presents challenges to the 
anesthesia provider, as it causes a 
reduction in cardiac output which 
can be amplified by anesthetic 
agents (Singh & Mehta, 2018).
• HFpEF is a complex medical 
syndrome that affects a significant 
portion of the population and poses 
many unique clinical considerations 
for the healthcare provider.
• It is important for healthcare 
providers to be aware of the 
pathophysiology and considerations 
related to HFpEF in order to make 
evidence-based decisions involving 
the care of patients who present 
with the disease.
• As the population ages, the
prevalence of HFpEF is increasing 
significantly (Tawil & Gelzinis, 
2016). 
• Although treatment for HFpEF does 
not exist, symptoms can be 
managed with medication and 
lifestyle changes.  The nurse is in a 
unique position to provide 
education to the HFpEF patient to 
improve quality of life (Cavalcanti & 
Pereira, 2014).
• As the ventricle hypertrophies and becomes stiff, the cardiac output will decrease. This 
causes blood to back up into the LA and into the pulmonary circulation. The backflow of 
blood into the pulmonary vasculature can cause pulmonary edema, and acute, life-
threatening disorder that must be managed in an acute care setting and may require 
advanced resuscitation techniques and aggressive medication and airway management. 
This acute on chronic exacerbation of HFpEF accounts for the majority of hospital 
admissions in patients 65 years of age or older (Farris et al., 2017).
• In an outpatient setting, the symptoms associated with HFpEF can cause a reduction in 
the quality of life for the patient without proper management through diet changes, 
lifestyle changes, and medication (Harper et al., 2018).
• Diuretics are the hallmark of HFpEF management because of their ability to reduce 
preload. If there is less preload, the heart may not struggle to pump an increased 
volume of blood forward, reducing the instances of acute on chronic exacerbations 
(Harper et al., 2018).
• Management can also include medications such as beta blockers, which contribute to a 
decrease in afterload that can augment the cardiac output, and ACE inhibitors, which 
can prevent remodeling of the heart muscle (Harper et al., 2017).
Figure 1. Specific biological phenotypes in HFpEF (Lewis et al., 2017).
Figure 2. Biological phenotypes in HFpEF (Lewis et al., 2017).
Figure 3. An illustration of heart
muscle hypertrophy in HFpEF 
("Diastolic Heart Failure," 2010).
